Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867359 · ClinicalTrials.gov registry record
The Genetic Characterization of Dementia
A clinical trial, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- 87
- Enrollment target
NCT01867359: Completed study, sponsored by National Institute on Aging (NIA).
NCT01867359 is a clinical trial that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01867359 has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- 87 participants
- Enrollment target
Study Summary
Background: \- Researchers are interested in learning more about dementia and its causes. They want to look at the genetic basis of dementia. Identifying genetic aspects of dementia may help provide better tests and treatments for it. It may also show rare gene variants that can cause or alter a person's risks for developing dementia. This study will look at people who have dementia, their family members, and healthy volunteers. Objectives: \- To study genetic influences on dementia. Eligibility: * Individuals who have been diagnosed with dementia. * Family members of individuals who have been diagnosed with dementia. * Healthy volunteers at least 18 years of age. Design: * Participants will be interviewed and answer questions about their medical history. They will also provide general information on the relatives' medical histories. * Participants will provide a blood sample for genetic testing. * Participants will remain on the study for up to 10 years. They will have regular visits to monitor their brain health and function. * Treatment will not be provided as part of this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2003-03-14 |
| Est. Completion | 2016-09-20 |
What the finished NCT01867359 record still lists
NCT01867359 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 87 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01867359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01867359 about?
NCT01867359 is a clinical study titled "The Genetic Characterization of Dementia". Background: \- Researchers are interested in learning more about dementia and its causes. They want to look at the genetic basis of dementia. Identifying genetic aspects of dementia may help provide better tests and treatments for it. It may also show rare gene variants that can cause or alter a pe...
What is the current status of trial NCT01867359?
This trial is currently completed. The enrollment target is 87 participants. The study started on 2003-03-14. Estimated completion is 2016-09-20.
Who is sponsoring clinical trial NCT01867359?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI